肺がん化学療法 将来への挑戦

出版社: 癌と化学療法社
著者:
発行日: 1988-10-13
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784906225101
電子書籍版: 1988-10-13 (初版)
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,925 円(税込)

商品紹介

昭和63年6月18日に行われた日本肺癌学会主催の第3回ワークショップ「肺がん化学療法ー将来への挑戦」の記録集。

目次

  • 表紙
  • 編集のことば
  • 執筆者一覧
  • 目次
  • 序説
  • I 基礎からみた肺癌化学療法発展のための条件
  • 薬剤感受性テストによって肺癌化学療法は進歩するか?
  • 癌治療の課題 : 抗癌剤耐性と転移
  • 肺癌治療とOncogene(肺癌の発生, 進展に関する遺伝子)
  • 肺癌治療とGrowth factor
  • 肺癌治療とMonoclonal antibody
  • II 他領域からみた肺癌化学療法への提言
  • 結核化学療法の歴史から見た肺癌の化学療法
  • 白血病・悪性リンパ腫の治療戦略の肺癌治療への応用
  • 骨髄移植の肺癌治療への導入
  • 睾丸腫瘍の集学的治療戦略の肺癌治療への導入
  • III 肺癌化学療法の現状打破のための条件
  • 切除不能肺癌の予後因子
  • Surgical adjuvant, neo-adjuvant chemotherapyの立場から
  • Combined radiotherapyの立場から-非小細胞肺癌について-
  • 肺癌化学療法の現況と将来への展望
  • 閉会の辞
  • 索引語
  • 監修者略歴
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

目次

P.3 掲載の参考文献
2) 許泰一, 土肥博雄:急性非リンパ性白血病の化学療法. カレントテラピー 6:578-582, 1988.
3) 尾山 淳, 森田皓三, 須知泰山・他:悪性リンパ腫の予後因子. 癌の臨床 34:705-713, 1988.
4) 山田龍作, 佐藤守男, 野村尚三・他:肝細胞癌に対する動脈塞栓療法-7年9か月, 529例の成績. 日本癌治療学会誌 21:1104-1106, 1986.
5) 犬山征夫:頭頸部癌に対する化学療法. 医学のあゆみ 141:661-665, 1987.
7) 古武敏彦, 三木恒治:睾丸腫瘍に対する化学療法後のSalvage Surgery. 癌と化学療法 4(5) Part II :1671-1979, 1987.
8) Aisner, J., Alberto, P., Comis, P. et al.:Role of chemotherapy in small cell lung cancer. A Concensus report of the IASLC Workshop. Cancer Treat Rept. 67:37, 44, 1983.
9) 福岡正博, 根来俊一:進行性非小細胞癌の化学療法. 医学のあゆみ 141:685-689, 1987.
P.15 掲載の参考文献
2) Shimizu, E., Saijo, N., Kanzawa, F. et al:Correlation between drug sensitivity determined by clonogenic cell assay and clinical effect of chemotherapy in patients with primary lung cancer. Jpn. J. Cancer Res. (Gann) 75:1030, 1984.
3) 藤本修一:癌の化学療法-治療成績向上のためのアプローチ(I) -. 薬事新報 No. 1427:261, 1987.
4) Ihde, D. C.:Personal communication
5) Gazdar, A. F., Tsai, C. M., Park, J. G. et al:Neurocrine differentiation in non-small cell lung cancer. Proceedigs of the First International Symposium of the Foundation for Promotion of Cancer Research 32, 1988.
7) Scheithauer, W., Clark, G. M., Salmon, S. E. et al:Model for estimation of clinically achievable plasma concentrations or investigational anticancer drugs in man. Cancer Treat. Rep. 70:1379, 1986.
8) Horiuchi, N. et al:Cancer Chemother. Pharmacol. (in press)
P.24 掲載の参考文献
2) Garlach, J. H., Endicott, J. A., Juranka, P. F. et al:Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324:485-489, 1986.
6) Hamada, H. and Tsuruo, T.:Purification of the 170- to 180- kilodalton membrane glyco-protein associated with multidrug-resistance:The 170- to 180-kilodalton membrane glyco-protein is an ATPase. J. Biol. Chem. 263:1454-1458, 1988.
7) Hamada, H., Hagiwara, K., Nakajima, T. et al:Phosphorylation of the Mr 170000 to 180000 glycoprotein specific to multidurg-resistant tumor cells:Effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 47:2860-2865, 1987.
8) Tsuruo, T., Iida, H., Tsukagoshi, S. et al:Overcoming of vincristine resistance in P388 leukemia, in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972, 1981.
9) Tsuruo, T., Iida, H., Tsukagoshi, S. et al:Increased accumulation of vincristine and Adri-amycin in drug resistant tumor cells following incubatiion with calcium antagonists and calmodulin inhibitors. Cancer Res. 42:4730-4733, 1982.
11) Tsuruo, T., Yamori, T., Naganuma, K. et al:Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Res. 43:5437-5442, 1983.
13) Sugimoto, Y., Oh-hara, T., Watanabe, M. et al:Acquisition of metastatic ability in hybrid-omas between two low metastatic clones of murine colon adenocarcinoma 26 defective in either platelet-aggregating activity or in vivo growth potential. Canctr Res. 47:4396-4401, 1987.
P.32 掲載の参考文献
2) Rodenhuis, S., Wetering, M. L, Mooi, W. J. et al:Mutational activation of the K-ras oncogene, a possibie pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317:929-935, 1987.
7) Brooks, B. J., Battey, J., Nau, M. M. et al:Amplification and expression of the myc gene in small-cell lung cancer. Advance in Viral Onocology 7:155-172, 1987.
13) Yokota, J., Wada, M., Yoshida, T. et al:Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes. Oncogene 2:607-611, 1988.
14) Yoshimoto, K., Shiraishi, M., Hirohashi, S. et al:Rearrangement of the c-myc gene in two giant cell carcinomas of the lung. Jpn. J. Cancer Res. 77:731-735, 1986.
19) Yokota, J., Akiyama, T, Fung, Y-K. T. et al:Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene (in press)
20) Shiraishi, M., Morinaga, S., Noguchi, M. et al:Loss of genes on the short arm of chromosome 11 in human lung carcinomas. Jpn. J. Cancer Res. (Gann) 78:1302-1308, 1987.
P.40 掲載の参考文献
1) McDonald, T. J., Jornvall, J. H., Nilssen, G. et al:Characterization of a gastrin-releasing peptide from porcine nonantral tissue. Biochem. Biophys. Res. Commun. 90:227-233, 1979.
2) Rosengurt, E. and Sinnert-Smith, J.:Bombesin Stimulation of DNA Synthesis and cell division in cultures of Swiss 3T3 cells. Proc. Nath. Acad. Sci. USA 89:2936-2940, 1983.
5) Cuttita, F., Carney, D. N. and Mulshine, J.:Bombesin-live peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (Lond.) 316:823-826, 1985.
7) Iwanaga, T.:Gastrin-releasing peptide (GRP) /bombesin-like immunoreactivity in the neurons and paraneurons of the gut and lung. Biomed. Res. 4:93-103, 1983.
10) Growcott, J. W., Jamiesen, A., Tarpey, A. V. et al:Further evidence for multiple tachykinin receptors. Eur. J. Pharmacol. 86:59-64, 1983.
14) Yamaguchi, K., Abe, K., Kameya, T. et al:Production and molecular size heterogenity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res. 43:3932-3939, 1983.
15) Bepler, G., Carney, D. N. Gazdar, A. F. et al:In vitro growth inhibition of human small cell lung cancer by physalaemin. Cancer Res. 47:2371-2375, 1987.
19) Veber, D. F., Saperstein, R. Nutt, R. F. et al:A super active cyclic hexapeptide analog of somatostatin. Life Sci. 31:1133-1140, 1982.
24) Rokaeus, A., Melander, T., Hokfelt, T. et al:A galanin-like peptide in the central nervous system and intestine of the rat, Neurosci Lett. 47:161-166, 1984.
25) Ahren, R., Arkhammar, P., Berggren, P. O. et al:Galanin inhibits glucose-stimulated insulin release by a mechanism involving hyperpolarization and Iowering of cytoplasmic free Ca2+ concentration. Biochem. Biopheps. Res. Commun. 140:1059- 1063, 1986.
26) 矢内原昇, 矢内原千鶴子, 井上 孝・他:腫瘍と発癌遺伝子産物. ホルモンと臨床 35:161-165, 1987.
P.53 掲載の参考文献
2) Takahashi, T., Ueda, R. Song, X. et al.:Two novel cell surface antigens on small cell lung carcinoma defined by mouse monoclonal antibodies NE-25 and PE--35. Cancer Res. 46:4770-4775, 1968.
3) Ueda, R., Takahashi, T., Watanabe, H. et al.:Serological and biochemical analysis of four antigens associated with small cell lung cancer., Lung cancer:in press
4) Watanabe, H., Takahashi, T., Ueda, R. et al.:Antigenic phenotype and biological characteristics of two distnct sublines derived from a small cell lung carcinoma cell lines. Cancer Res. 48:2544-2549, 1988.
6) World Health Organization. The WHO histlogical typing of lung tumors. Ed. 2. Am. J. Clin. Pathol. 78:123-136, 1982.
8) Gazdar, A. F., Carney, D. N, Nau, M. M. et al.:Characterization of varaint subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45:2924-2930, 1985.
10) Graziano, S. L., Cowan, B. Y., Carney, D. N. et al.:Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. Cancer Res. 47:2148-2155, 1987.
11) Goodwin, G. and Baylin, S. B.:Relationships between neuroendocrine differentiation and sensitivity to gamma-radiation in culture line OH-1 of human small cell lung carcinoma. Cancer Res. 42:1361-1367, 1982.
13) Whang-Peng, J., Kao-Shan, C. S., Lee, E. C. et al.:A specific chromosome defect associated with human small-cell lung cancer:Deletion 3p (14-23) . Science 215:181-182, 1982.
14) Whang-Peng, J., Bunn, P. A., Kao-Shan, EC. et al.:A non-random chromosomal abnormality, del3p (14-23) in human small cell lung cancer. Cancer Genet. Cytogenet. 6:119- 134, 1982.
22) Sao, H., Morishima, Y., Ueda, R. et al.:Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia. Jpn. J. Cancer Res. (Gann) 76:1212-1221, 1985.
23) Morishima, Y., Sao, H., Ueda, R. et al.:Preliminary clinical trial of autologous bone marrow transplantation after in vitro monoclonal antibody and complement treatment in null cell-type acute lymphocytic leukemia. Jpn. J. Cancer Res. (Gann) 76:1222-1229, 1985.
P.66 掲載の参考文献
1) National Tuberculosis Institute, Bangalore:Tuberculosis in a rural population of South India. A Five-year epidemiological study. Bull. Wld. Hlth. Org. 51:473-488, 1974.
2) 砂原茂一:日本結核病学会における結核研究の歩み, 化学療法. 結核 50:528-534, 1975.
3) 金井興美:結核化学療法100年の展望, (その1) 結核化学療法剤開発のあゆみ. 結核 57:643-651, 1982
4) Medical Research Council investigation:Streptomycine treatment of pulmonary tuberculosis. Br. Med. J. 2:769-782, 1948
5) Medical Research Council investigation:The prevention of streptomycin resistance by combined chemotherapy. Br. Med. J. 1:1157-1162, 1952
6) Tucker, W. B.:The evolution of the cooperative studies in the chemotherapy of tuberculosis of Vetrans Adminstration and Armed Force of the U. S. A. -an account of the physician in clinical pharmacology-. Advance in Tuberc. Research. 10:1-68, 1960.
7) American Trudeau Society:Changing concepts and modern treatment of tuberculosis. Amer. Rev. Tuberc. 70:930-948, 1954
8) 岩崎龍郎:肺結核症の化学療法に関する臨床的並びに病理形態学的研究. 結核 30 (増刊号) :1-12, 1955
9) 文部省科学研究費「化学療法による結核治癒機転」研究班:化学療法を目標とした肺結核の病型分類. 日本医事新報 1752:37-38, 1957, 化学療法による肺結核の病状経過判定. 日本医事新報 1770:20-22, 1958.
10) Dubos, R. T. and Middlebroook, G.:Media for tubercle bacilli. Amer. Rev. Tuberc. 56:334-345, 1947.
11) Youmans, G. P. and Yomans, A. R.:The relation between the size of the infecting dose of tubercle bacilli and the survival time of mice. Amer. Rev. Tuber. 64:534-540, 1951.
12) 国立療養所化学療法共同研究班:「結核化学療法の対照試験 (1957-1966) 」. 厚生省国立療養所化学療法共同研究班編, 国立療養所東京病院, 東京, pp. 1-326, 1970.
13) 国立療養所化学療法共同研究班:「結核化学療法の対照試験2. (1967-1976) 」. 厚生省国立療養所化学療法共同研究編, 国立療養所東京病院, 東京, pp. 1-103, 1980.
14) 島村喜久治:第41回結核病学会シンポジウムII, 各種結核化学療法の比較検討- 2. 国立療養所化学療法共同研究班の成績から. 結核 41:436-442, 1970.
15) 堂野前維摩卿, 山本和男:空洞の化学療法, 「結核の化学療法」(北本治, 藤田真之助編) , 医学 書院, 東京, pp. 214-243, 1959.
16) 国立療養所化学療法共同研究班:無作為割当による肺結核化学療法方式の比較, 第2次共同研究報告, INH大量, SMとINHの切り換えおよびINH誘導体の意義についての検討. 日本胸部臨床 21:768-780, 1962;21:860-875, 1952.
17) 国立療養所化学療法共同研究班:無作為割当による肺結核化学療法方式の比較, 第4次共同研究報告, くるくる療法, 皮質ホルモン併用療法, INH大量療法, PAS少量療法の評価. 日本胸部臨床 23:585-601, 1964.
18) 国立療養所化学療法共同研究班:二次薬治療における1剤, 2剤および3剤方式の比較-第7次B研究. 結核 43:199-207, 1968.
19) 国立療養所化学療法共同研究班:Rifampicinを使用した初回治療の成績-第13次国療化研A研究-. 結核 48:235-245, 1973.
20) East Africca/Brit. Mrd. Rsear. Councils:Controlled clinical trial of four short-course (6-months) regimen of chemotherapy for treatment of pulmonary tuberculosis (1st-3rd report) . Lancet 1:1079-1085, 1972;1:1331-1338, 1973;2:237-240, 1974.
21) 日本結核病学会治療専門委員会:肺結核化学療法の期間に関する見解. 結核 55:189-193, 1980.
22) 亀田和彦, 岩井和郎, 岩崎龍郎・他:肺結核の切除病巣内結核菌培養に関する共同研究. 結核 45:143-151, 1970.
23) Fox, W. and Mitchison, D. A.:Short-course chemotherapy for pulmonary tuberculosis. Am. Rev. Respir. Dis. 111:325-353, 1975. Fox, W.:第53回日本結核病学会招請講演, 短期化学療法の現状, 特に処方と機序に関連して. 結核 53:503-509, 1978.
24) 木野智慧光:肺結核の初回治療. 「内科Mook, 36, 結核」, 金原出版, pp. 111-120, 1987.
P.77 掲載の参考文献
1) DeVita, V. T., Serpick, A. A., Carbone, P. P. et al:Combination chemotherapy in the treatment of advanced Hodgkins disease. Ann. Intern. Med. 73:881-895, 1970.
3) Skipper. H. E., Schabel, F. M. and Wilcox, W. S, :Experimental evaluation of potencial anticancer, agents. XII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother. Rep. 35:1-111, 1964.
4) Coltman, C. A.:Chemotherapy of advanced Hodgkin's disease. Semin. Oncol. 7:155-173, 1980.
6) Connors, J. M. and Klimo, P.:MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease. Semin. Hematol. 24 (Suppl 1) :35-40, 1987.
7) Coleman, M., Gerstein, G., Topilow, A. et al:Advancesof chemotherapy for large cell lymphoma. Semin. Hematol. 24(Suppl 1) :8-20, 1987.
8) DeVita, V. T.:The evolution of chemotherapy of lymphomas of adults. LEUKEMIA 1:467-485, 1987.
10) 多田敦彦, 大熨泰亮, 林 恭一・他:びまん性大細胞型非ホジキンリンパ腫に対する多剤併用療法の治療成績-Adriamycin を含む多剤併用療法の有用性について-癌と化学療法 14:2692-2696, 1987.
11) 水田潤, 吉田光雄, 多田敦彦・他:中高悪性度non-Hodgkinリンパ腫(NHL) に対するCHOP-B/POEM-B交替療法の試み. 第29回日本臨床血液学会総会抄録集 p. 221, 1987.
12) Goldie, J. H. and Coldman, A. J.:A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63:1727-1733, 1979.
13) Goldie, J. H., Coldman, A. J. and Gudauskas, G. A.:Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat. Rep. 66:439-449, 1982.
17) Shah, A., Murray, N., Osoba, D. et al:CODE-A dose-intense chemotherapy regimen for lung cancer. Proc. ASCO 7:209, 1988.
P.88 掲載の参考文献
1) 正岡 徹:骨髄移植. 日本内科学会誌 76:654-657, 1987.
2) Teshima, H. et at:Interstitial pueumonitis in allogeneic bone marrow transplantation. Bone Marrow Transplantation 1:179, 1986.
3) Nakamura, H. et al:Significance of Graft versus Host disease in allogeneic bone marrow transplantation. Acta Haem. JPN. 50:1627-1633, 1987.
4) 石原重彦・他:自家骨髄移植による神経芽細胞腫の治療. 小児外科 19(11) :1413-1421, 1987.
6) 柴田弘俊・他:骨髄移植における人尿由来コロニー刺激因子(CSF-Hu) の二重盲検法による効果の検討. 今日の移植. 印刷中, 1988.
7) Abrams, R. A. et al:Bone marrow auto transplantation in man. Lancet (oct.) 25:960-962, 1986.
P.112 掲載の参考文献
1) 厚生省大臣官房統計情報部人口動態統計課:人口動態, 1985.
2) DeVita, V. T. Jr.:Principle of chemotherapy. Cancer Principle and Practice of oncology vol. I, pp. 257-285, J. B. Lippincott Company, Philadelphia, 1985.
4) Aisner, J., Alberto, P., Bitran, J. et al:Role of chemotherapy in small cell lung cancer:A consensus report of the international association for the study of lung cancer workshop. Cancer Treat. Rep. 67:37-43, 1983.
5) Gralla, R. J., Casper, E. S., Kelsen, D. P. et al:Cisplatin and vindesin combination chemotherapy for advanced carcinoma of the lung:A randomized trial investigating two dosage schedules. Ann. Intern. Med. 95:414-420, 1981.
6) Rapp, E., Pater, J., Willan, A et al:A comparison of best supportive care to two regimens of combination chemotherapy in the management of advanced non-small cell lung cancer. A report of a Canadian multicentre trial. Proc. Am. Soc. Clin. Oncol. 6:168, 1987.
7) 富永祐民:Cox の重回帰型生命表法 (比例ハザードモデル) の理論と応用. 治療効果判定のための実用統計学, pp. 123-134, 蟹書房, 東京, 1985.
8) Stanley, K. E.:Prognostic factors in lung cancer. Lung Cancer, pp. 41-66, Churchill Livingstone, New York, 1985.
9) O'Connell, J. P., Kris, M. G., Gralla, R. J. et al:Analysis of factors predicting outcome in 350 patients with stage III non-small cell lung cancer receiving high-dose cisplatin/ vinca alkaloid regimens. Proc. Am. Soc. Clin. Oncol. 4:190, 1985.
10) φsterlind K.:Prognostic factors in small cell lung cancer:An analysis of 874 consecutive patients. Lung Cancer 3, pp. 129-152, Martinus Nijhoff, Boston, 1985.
11) Souhami, R. L., Bradbury, I., Geddes, D. M. et al:Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 45:2878-2882, 1985.
P.123 掲載の参考文献
2) Ayoub, J., Duranceau, A., Lorange, A. et al:Effectiveness of adjuvant chemotherapy in operable non-small cell lung cancer [abstruct]. In Proceedings of the IV World Conference on Lung Cancer, Toronto, Canada, p. 32, 1985.
5) Shield, T. W., Higgins, G. A., Lawton, R. et al:Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma. J. Thorac. Cardiovasc Surg. 59:49-61, 1970.
7) Skarin, A., Veeder, M., Malcolm, A. et al:Chemotherapy (CAP) prior to radiotherapy (RT) and surgery in marginally resectable non-small cell lung cancer (NSCLC) [abstruct]. Proc. Am. Soc. Clin. Oncl. 1:143, 1982.
8) Folman, R., Rosman, M. and Auerbach, S.:Mitomycin-C, vinblastine and cis-platinum in the combined modality treatment of non-small cell lung cancer [abstruct]. Proc. Am. Soc. Clin. Oncol. 3:232, 1984.
9) Spain, R., Amderson, P., Speer, J. et al:Improved survival with mitomycin-C, cis-platinum and continuous vinblastine infusion plus radiation therapy or surgery over RT alone for stage III limited, initially inoperable, non-small cell lung cancer [abstruct]. In Proceeding of the IV World Conference on Lung Cancer, Tronto, Canada, pp. 33, 1985.
12) Trybula, M., Taylor, S. G. Bonomi, P. et al:Preoperative simultaneous cisplatin/5-fluorouracil and radiotherapy in clinical stage III, non-small cell bronchogenic carcinoma [abstruct]. Proc. Am. Soc. Clin. Oncol 4:182, 1985.
13) Strauss, G., Sherman, D., Schwartz, J. et al:Combined mordality therapy for regionally advanced stage III non-small cell carcinoma of the Iung employing neoadjuvant chemotherapy, radiotherapy and surgery [abstruct]. Proc. Am. Soc. Clin. Oncol. 5:172, 1986.
14) Kris, M. G., Gralla, R. J., Martini, N. et al:Trial of pre-operative cisplatin plus vinca alkaloid chemotherapy in non-small cell lung cancer patients with clinically apparent, ipsilateral, mediastinal lymph node metastases [abstruct]. Proc. Am. Soc. Clin. Oncol. 6:177, 1987.
16) Goldie, J. H., Coldman, A. J. and Gudanskas, G. A.:Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat. Rep. 66:439-449, 1982.
18) Meyer, J. A., Gullo, J. J., Ikins, P. M. et al:Adverse prognostic effect of N2 disease in treated small cell carcinoma of the lung. J. Thorac. Cardiovasc. Surg. 88:495-501, 1984.
P.134 掲載の参考文献
2) Cox, J. D., Samson, M. K., Herskovic, A. M. et al:Cisplatin and etoposide befor definitive radiation therapy for inoperable squamous carcinoma, adenocarcinoma, and large cell carcinoma of the lung:A phase I-II study of the Radiation Therapy Oncology Group. Cancer Treat. Rep. 70:1219-1220, 1986.
3) Osoba, D., Rusthoven, J. J., Evans, W. K. et al:Combined chemotherapy and radiation therapy for non-small-cell lung cancer. Semin Oncol 13:121-124, 1986.
4) Blum, R. H., Cooper, J., Schmidt, A. M. et al:Cisplatin and vinblastine chemotherapy for matastatic non-small cell carcinoma followed by irradiation in patients with regional disease. Cancer Treat. Rep. 70:333-337, 1986.
5) Eagan, R. T., Ruud, C., Lee, R. E. et al:Pilot study of induction therapy with cyclo-phosphamide, doxirubicin and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III Mo non-small lung cancer. Cancer Treat. Rep. 71:895-900, 1987.
6) Friess, g. G., Baikadi, M. and Harvey, W. H.:Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer. Cancer Treat. 71:681-684, 1987.
9) Van Houtte, P., Klastersky, J., Nguyen, H. et al:Comparative randomized study of chest radiotherapy preceded or not by chemotherapy with cisplatin, etoposide and vindesine for the treatment of non-small cell lung cancer (NSCLC) Pro. ASCO. 25:785, 1984.
10) Trovo, M. G., Roncadin, M., Minatel, M. et al:End result of randomized study comparing radiotherapy (RT) and RT followed by CAMP regimen in patients with stage III epidermoid bronchogenic carcinoma. Pro. ASCO. 5:187, 1986.
11) Morton, R. F., Jett, J. R., Mher, L. et al:Randomized trial of thoratic radiation therapy (TRT) with or without chemotherapy for treatment locally unresectable non-small cell lung cancer (NSCLG) . Pro. ASCO. 7:200, 1988.
12) Dillman, R. O., Seagren, S. L., Propert, K. et al:Protochemotherapy improves survival in regional non-small cell lung cancer. Pro. ASCO. 7:195, 1988.
13) 宮本忠昭, 寺島東洋三:放射線と化学療法の併用. 癌放射線療法, 柄川順編, 篠原出版, p. 55, 1987.
14) 森田皓三:放射線治療と薬剤との併用. 癌と化学療法 14:1531-1537, 1987.
17) Weiden, P.:Preoperative chemoradiotherapy in stage III non-small cell lung cancer (NS-CLG) . A phase II study of the lung cancer study group (LCSG) . Pro. ASCO. 6:185, 1987.
18) Sherman, D., Strauss, G., Schwartz, J. et al:Combined modality therapy for regionally advanced stage III non-small cell carcinoma of the lung employing neoadjuvant chemotherapy, radiotherapy and surgery. Pro. ASSO. 6:167, 1987.
19) Bonomi, P., Rowland, K., Taylor, S. G. et al:Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouacil, and simultaneous split-couse radiation therapy in stage III non-small-cell bronchogenic carcinoma. Semin. Oncol. 13:115-120, 1986.
P.145 掲載の参考文献
1) Greco, F. A.:Seminars in Oncol. 13:92-96, 1986.
3) Dillman, R. O., Seegren, S. L, Propert, V. et al:Protochemotherapy improves survival in regional non small cell lung cancer. Proc. of ASCO. 753, 1988.
5) Saijo, N., Shinkai, T., Eguchi, K. et al:Progress in chemotherapy for small and non-small cell lumg cancer in Japan. Proc. of first International Symposium of the Foundation for Promotion of Cancer Research (Fundamental and clinical research in lung cancer) pp. 54-55, 1988.
6) Saijo N, Shimizu E. Eguchi K. et al:Effect of peplomycin plus carbazilquinone and mitomycin C on non-small cell carcinoma of the lung. Cancer Treat. Rep. 67:385-387, 1983.
7) Shinkai T, Saijo N, Tominaga K. et al:Comparison of vindesine plus cisplatin or mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat. Rep. 69:945-951, 1985.
8) Shinkai, T., Saijo, N, Eguchi, K. et al:Cisplatin and Vindesine combination chemotherapy for non-small cell lung cancer:A ramdomized trial comparing two dosages of cisplatin. Jpn. J. Cancer Res. (Gann) 77:782-789, 1986.
9) Shinkai, T., Saijo, N., Eguchi, K. et al:Comparison of the effect of vindesine (V) + cisplatin (P) vs V+P+ mitomycin C against non-small cell lung cancer. Proc. 5th Int. Cong. for lung Cancer, 1988.
10) 西脇 裕:私信
13) 福岡正博, 根来俊一:進行非小細胞肺癌の化学療法. 医学のあゆみ 141:685-689, 1987.
16) Yokota, J., Wada, M., Shimosato, Y. et al:Molecular genetic analysis of chromosome and oncogene abnormalities in lung cancer. Proc. the First International Symposium of the Foundation for Promotion of Cancer Research:Fundamental and Clinical Research in Lung Cancer, pp. 28-29, 1988.
17) Gazder, A. F., Fai, C. M., Park, J. G. et al:Neuroendocrine differentiation in non-small cell lung cancer. Incidence, biological properties and relative chemosensitivity Proc, of the First International Symposium of the Foundation for Promotion of Cancer Research Fundamental and Clinical Research in Lung Cancer, pp. 32-33, 1988.
19) Tamura, T., Sasaki, Y., Eguchi, K. et al :Phase II trial of carbo platin on small cell lung cancer. Jpn. J. Clin. Oncol 18:27-32, 1988.
20) Aisner, J.:Identification of new drug in small cell lung cancer:Phase II agents first? Cancer Treat. Rep. 71:113-1134, 1987.
21) Aisner J.:Personal communication.
22) 中山治彦, 西條長宏:肺癌に対する neo-adjuvant chemotherapy. 治療 70:179-186, 1988.

最近チェックした商品履歴

Loading...